Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of glucarpidase (OP-07) for delayed methotrexate excretion after high-dose methotrexate
jRCT2080225030Phase 2Completed
- Sponsor
- Ohara Pharmaceutical Co., Ltd.
- Start
- Jan 2020
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glucarpidase in Methotrexate overdose and acute kidney failure (AKF), sponsored by Ohara Pharmaceutical Co., Ltd. Primary endpoint: Primary efficacy (concentration improvement rate). Started Jan 2020; status: completed.
02
Drugs
glucarpidase
03
Conditions
Methotrexate overdoseacute kidney failure (AKF)
Beyond the preview
Go deeper on jRCT2080225030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225030.